Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD, page-209

I said increases by mistake when I should have said decreases.

Eg. In Kasikis et al 2021 - a document written by four then employees of Mesoblast and two consultants that received consulting fees from Mesoblast according to the competing interest disclamer. And A document that is absolutely going to be referenced in Mesoblasts submission because its the paper that reports "Mesenchymal stromalcell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers".

This is stated - "In vitro, MSCs have several immunomodulatory properties and reduce the secretion of inflammatory cytokines such as IFNy and TNFa by alloractive T cells [8].

And [8] - the cited authority offered as support - the only one is - Aggarwarl and Pittenger 2005. "Human mesenchymal stem cells modulate allogeneic immune cell responses".

By the way Aggarwarl and Pittenger were Osiris Therapeutics employees back when and the inventors on an existing MSB patent.

So the authority of the sources of the statement I'm pointing at and the (by 2023 standards old) science that those sources are ultimately referring back to is all there. All discoverable.